The research seeks to evaluate the drug's effectiveness in reducing pain and persistent joint inflammation, which affects many patients months after they have overcome the acute phase of the infection.
Photo: Carlos Rafael
The Phase II clinical trials of Soberana Plus in convalescents of COVID 19 will include 450 people and will broaden the inclusion criteria compared to Phase I, informed today an expert from the Finlay Vaccine Institute (IFV), the entity that developed this vaccine candidate against COVID-19.
Read more Phase II clinical trial of vaccine candidate Soberana Plus to include 450 COVID 19 convalescents
Solidarity organizations based in the United States delivered on Saturday a donation valued at more than 70 thousand dollars to support the recovery of the western province of Pinar del Río, hit by Hurricane Ian.
Page 376 of 504